FDA Approves Medtronic’s Neurostimulators for Diabetic Peripheral Neuropathy

The FDA has approved Medtronic’s Intellis rechargeable neurostimulator and Vanta recharge-free neurostimulator to treat chronic pain associated with diabetic peripheral neuropathy.

The approval is a new indication for the company’s spinal cord stimulation devices, which feature multiple programming options to personalize patient therapy and unrestricted magnetic resonance imaging (MRI) access.

Diabetic peripheral neuropathy is a progressive neurological disorder that affects approximately 30 percent of people with diabetes, significantly impacting their quality of life and functional ability.